CureVac touts older adult data for GSK-partnered Covid-19, flu candidates
Germany’s CureVac reported data Monday on older patients to beef up plans to advance vaccines for Covid-19 and seasonal flu.
In short, the Covid-19 data reveal the vaccine candidate, known as CV0501 targeting Omicron’s BA.1 variant, boosted titers of neutralizing antibodies by 13.3-fold after four weeks at the lowest 12 µg dose level. The data in these cohorts are still small, with 10 patients enrolled per dose. Some patients also received 25 and 50 µg doses.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,900+ biopharma pros reading Endpoints daily — and it's free.